QQQ $ 594.74 $ -16.89 (-2.76 %)
DIA $ 461.13 $ -5.55 (-1.19 %)
SPY $ 660.17 $ -12.73 (-1.89 %)
TLT $ 89.11 $ 0.12 (0.13 %)
GLD $ 373.53 $ -1.65 (-0.44 %)
$ 1.17
$ 1.21
$ 1.07 x 300
$ 1.11 x 31
$ 1.10 - $ 1.21
-- - --
--
na
--
--
--
TBD
--
-- (--)
--
TBD --
How to Read 10-K & 10-Q Reports To View SEC Filing Reports, Please Register or Sign In
# Filing Date Period End Date Type Report Link
No Data found
Guide for Analyst Ratings To View Analyst Ratings, Please Register or Sign In
# Date Analyst Firm Upside/Downside Price Target Change Rating Change Current Rating

News

OPINIONS

 evogene-q3-eps-031-beats-041-estimate-sales-312000k-miss-650000k-estimate

Evogene (NASDAQ:EVGN) reported quarterly losses of $(0.31) per share which beat the analyst consensus estimate of $(0.41) by 24...

 preview-evogenes-earnings
Preview: Evogene's Earnings
08/18/2025 15:02:56

 lake-street-maintains-buy-on-evogene-lowers-price-target-to-35

Lake Street analyst Ben Klieve maintains Evogene (NASDAQ:EVGN) with a Buy and lowers the price target from $5 to $3.5.

 evogene-q1-eps-038-beats-063-estimate-sales-244m-miss-442m-estimate

Evogene (NASDAQ:EVGN) reported quarterly losses of $(0.38) per share which beat the analyst consensus estimate of $(0.63) by 39...

 icl-to-acquire-majority-activity-of-evogenes-subsidiary-lavie-bio-term-not-disclosed

Lavie Bio improves agriculture productivity and sustainability through microbiome-based ag-biological productsREHOVOT, Israel, ...

 evogene-q4-2024-gaap-eps-006-may-not-be-comparable-to-072-estimate-sales-161m-miss-363m-estimate

Evogene (NASDAQ:EVGN) reported quarterly earnings of $0.06 per share which beat the analyst consensus estimate of $(0.72) by 10...

CLASS ACTION DEADLINES - JOIN NOW!

NEW CASE INVESTIGATION